Share

Save

A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors

PHASE1RECRUITING

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ES009 administered intravenously to subjects with advanced solid tumors.

info
Simpliy with AI

Study details:

ES009 is a recombinant humanized IgG4 monoclonal antibody that specifically targets and blocks LILRB2. By reprograming suppressive myeloid cells into pro-inflammatory phenotypes, ES009 reshapes the immunosuppressive tumor microenvironment into an immune-favorable one to combat cancer development and progression. This is a first-in-human, open-label, multicenter, non-randomized study designed to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD), optimal biological dose (OBD), and recommended phase 2 dose (RP2D) of ES009 by evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ES009 administered intravenously to subjects with advanced solid tumors.

info
Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  • Capable of giving signed informed consent.
  • Histological or cytological documentation of unresectable locally advanced or metastatic solid tumors, if 1) disease has progressed despite standard therapy, and no further standard therapy exists; or 2) standard therapy has proven to be ineffective or intolerable or is considered inappropriate.
  • At least one measurable lesion per RECIST v1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.
  • Life expectancy of at least 12 weeks.
  • Adequate hematologic, hepatic, renal and coagulation function per protocol.
  • Male and female subjects of childbearing potential must be willing to completely abstain or agree to use a highly effective method of contraception per protocol.
  • Exclusion criteria

  • Any prior therapy targeting LILRB2.
  • Receipt of any investigational therapies within 28 days or 5 half-lives prior to the first dose of study drug.
  • Prior treatment with the following therapies:• Anticancer therapy within 28 days or 5 half-lives of the drug prior to the first dose of study drug, whichever is shorter. Exception: hormonal replacement therapy.• A wash out of at least 2 weeks before the start of study drug for radiation to the extremities and 4 weeks for radiation to the chest, brain, or visceral organs is required.
  • Prior allogeneic or autologous bone marrow transplantation or solid organ transplantation.
  • Toxicity from previous anticancer treatment per protocol.
  • Treatment with systemic immunosuppressive medications within 4 weeks prior to the first dose of study drug with certain exceptions.
  • Subjects who received transfusion of blood products (including platelets or red blood cells), G-CSF, GM-CSF, recombinant erythropoietin, or recombinant thrombopoietin within 14 days prior to the first dose of study treatment.
  • Major surgery within 4 weeks prior to the first dose of study treatment.
  • Live vaccine therapies within 4 weeks prior to the first dose of study treatment.
  • Recent history of allergen desensitization therapy within 4 weeks prior to the first dose of study treatment.
  • Known allergies to CHO-produced antibodies.
  • Invasive malignancy or history of invasive malignancy other than disease under study within the last two years with certain exceptions.
  • CNS metastases with certain exceptions.
  • Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications.
  • Active interstitial lung disease (ILD) or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
  • Active infection requiring systemic therapy, known human immunodeficiency virus (HIV) infection, or positive test for hepatitis B active infection (HBsAg) or hepatitis C active infection (hepatitis C antibody).
  • Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases, or otherwise stable chronic liver disease per investigator assessment).
  • History or evidence of cardiac abnormalities.
  • Pregnant or nursing females.
  • Any known, documented, or suspected history of illicit substance abuse that would preclude subject from participation, unless clinically justified.
  • Any other disease or clinically significant abnormality in laboratory parameters, including serious medical or psychiatric illness/condition, which in the judgment of the Investigator might compromise the safety of the subject or integrity of the study, interfere with the subject participation in the trial or compromise the trial objectives.
  • Involvement in the planning and/or conduct of the study (applies to both Sponsor/CRO staff and staff at the study site)
  • Judgment by the Investigator that the subject is unlikely to comply with study procedures, restrictions and requirements.
  • info
    Simplify with AI

    Eligibility

    Age eligible for study : 18 and older

    Healthy volunteers accepted : No

    Gender eligible for study: All

    Things to know

    Study dates

    Study start: 2023-09-07

    Primary completion: 2024-08-15

    Study completion finish: 2025-08-15

    study type

    Study type

    TREATMENT

    phase

    Phase

      PHASE1

    trial

    Trial ID

    NCT06007482

    Intervention or treatment

    DRUG: ES009

    Conditions

    • Advanced Solid Tumor

    Find a site

    Closest Location:

    Peninsula and South Eastern Oncology and Haematology Group

    Research sites nearby

    Select from list below to view details:

    • Peninsula and South Eastern Oncology and Haematology Group

      Frankston, Not Specified, Australia

    • St George Private Hospital

      Kogarah, Not Specified, Australia

    • Scientia Clinical Research

      Randwick, Not Specified, Australia

    • Sunshine Coast University Private Hospital

      Sunshine Coast, Not Specified, Australia

    Loading...

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    How is the study designed?

    Participant Group/ArmIntervention/Treatment
    EXPERIMENTAL: Dose Escalation Cohort
    • ES009 monotherapy dose level will be escalated in participants with advanced solid tumors.
    DRUG: ES009
    • ES009 is administered via intravenous infusion, once every 21 days.

    What is the study measuring?

    Primary outcome

    Primary Outcome MeasurePrimary Outcome DescriptionPrimary Outcome Time Frame
    The frequency and severity of adverse events of ES009Adverse events will be assessed and assigned by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.1-3 years
    Maximum tolerated dose (MTD) of ES009The MTD of ES009 will be determined.1-3 years
    Optimal biological dose (OBD) of ES009The OBD of ES009 will be determined.1-3 years
    Recommended phase 2 dose (RP2D) of ES009The RP2D of ES009 will be determined.1-3 years
    Maximum administered dose (MAD) of ES009The MAD of ES009 will be determined.1-3 years

    Secondary outcome

    Secondary Outcome MeasureSecondary Outcome DescriptionSecondary Outcome Time Frame
    Maximum observed serum concentration (Cmax) of ES009Maximum observed serum concentration (Cmax) of ES009 will be measured.1-3 years
    Trough observed serum concentration (Ctrough) of ES009Trough observed serum concentration (Ctrough)of ES009 will be measured.1-3 years
    Area under the serum concentration time curve (AUC) of ES009Area under the serum concentration time curve (AUC) of ES009 will be measured.1-3 years
    Time to Cmax (Tmax) of ES009Time to Cmax (Tmax) of ES009 will be measured.1-3 years
    The terminal elimination half life of ES009The terminal elimination half-life (t 1/2) of ES009 will be measured.1-3 years
    Immunogenicity of ES009Frequency of anti-drug antibodies (ADA) against ES009 will be determined.1-3 years
    Preliminary antitumor activity of ES009Tumor response will be measured by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1) by Investigator assessment.1-3 years

    Frequently Asked Questions

    Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

    No questions submitted. Be the first to ask a question!

    You may be eligible to participate in this trial based on your search.Apply for study
    Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

    References

    Clinical Trials Gov: A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors

    Other trails to consider

    Top searched conditions